P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE

• COATES T.,
• LAL A.,
• BROWN R.,
• KALFA T.,
• KWIATKOWSKI J.,
• BREVARD J.,
• TRENOR C.,
• WOOD K.,
• SHETH S.

Affiliations

COATES T.

1 University of Southern California Keck School of Medicine, Los Angeles, UNITED STATES

LAL A.

2 University of California San Francisco, San Francisco, UNITED STATES

BROWN R.

3 Children’s Healthcare of Atlanta, Atlanta, UNITED STATES

KALFA T.

4 Cincinnati Children’s Hospital Medical Center, Cincinnati, UNITED STATES

KWIATKOWSKI J.

5 Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, UNITED STATES

BREVARD J.

6 Forma Therapeutics, Inc., Watertown, UNITED STATES

TRENOR C.

6 Forma Therapeutics, Inc., Watertown, UNITED STATES

WOOD K.

6 Forma Therapeutics, Inc., Watertown, UNITED STATES

SHETH S.

7 Weill Cornell Medicine, New York, UNITED STATES